A growing concerted movement to open up clinical research to all people is building momentum. We see the trends targeting “underrepresented” populations as a seemingly ubiquitous mission. The movement to make cancer clinical trials more reflective of the general population is no exception. The use of expanded clinical trial inclusion criteria would almost double the percentage of eligible patients for enrollment, reports the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research.
At the 2019 ASCO session, R. Donald Harvey, associate professor of hematology, pharmacology and medical oncology and the director of the Phase I Clinical Trials Unit at Winship Cancer Institute of Emory University, discussed the pros and cons of expanding clinical trials to be more inclusive and consequently, reflective of the general patient population.
Donald Harvey, Winship Cancer Institute of Emory UniversitySource: Cure Today